Analyzing Axovant Sciences (AXON) and Its Competitors

Axovant Sciences (NASDAQ: AXON) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Axovant Sciences to related companies based on the strength of its risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.


This table compares Axovant Sciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Axovant Sciences N/A -154.21% -99.83%
Axovant Sciences Competitors -5,322.24% -84.37% -35.66%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Axovant Sciences and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axovant Sciences 0 5 5 0 2.50
Axovant Sciences Competitors 951 3404 11905 239 2.69

Axovant Sciences presently has a consensus price target of $14.75, indicating a potential upside of 507.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.51%. Given Axovant Sciences’ higher possible upside, equities research analysts clearly believe Axovant Sciences is more favorable than its peers.

Valuation & Earnings

This table compares Axovant Sciences and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Axovant Sciences N/A -$180.95 million -1.05
Axovant Sciences Competitors $290.27 million $35.99 million 56.13

Axovant Sciences’ peers have higher revenue and earnings than Axovant Sciences. Axovant Sciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

96.9% of Axovant Sciences shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 72.4% of Axovant Sciences shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Axovant Sciences peers beat Axovant Sciences on 8 of the 12 factors compared.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company’s pipeline also includes RVT-103 and RVT-104.

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with's FREE daily email newsletter.

Leave a Reply